Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 28, 2025 16:53 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T...
March 31, 2025 07:00 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T...
March 27, 2025 07:00 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T...
March 05, 2025 07:00 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Presented updated data from ongoing ALLOHA™ Phase 1 heme trial at the 66th ASH Annual Meeting and Exposition IND application cleared for seventh TCR in PLEXI-T™ Phase 1 solid tumor program;...
February 27, 2025 07:00 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T...
February 18, 2025 07:00 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

WALTHAM, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T...
December 26, 2024 07:00 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T...
December 23, 2024 07:00 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T...
December 09, 2024 17:45 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0.14) No dose-limiting toxicities...
December 05, 2024 08:00 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

WALTHAM, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T...